{"id":"intravenous-thrombolysis-agents","safety":{"commonSideEffects":[{"rate":"0.5–1.5","effect":"Bleeding (intracranial hemorrhage)"},{"rate":"5–15","effect":"Systemic bleeding"},{"rate":null,"effect":"Reperfusion arrhythmias"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Allergic reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These agents work by activating the fibrinolytic cascade, converting the inactive zymogen plasminogen into its active form, plasmin. Plasmin then degrades fibrin cross-links that form the structural basis of blood clots, thereby dissolving thrombi and restoring perfusion to ischemic tissue. Common agents in this class include tissue plasminogen activator (tPA), streptokinase, and urokinase.","oneSentence":"Intravenous thrombolysis agents dissolve blood clots by converting plasminogen to plasmin, which breaks down fibrin and restores blood flow in occluded vessels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:45.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Acute myocardial infarction"},{"name":"Pulmonary embolism"},{"name":"Deep vein thrombosis"}]},"trialDetails":[{"nctId":"NCT05752916","phase":"PHASE4","title":"Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-06-02","conditions":"Acute Ischemic Stroke","enrollment":570},{"nctId":"NCT07119021","phase":"PHASE4","title":"Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)","status":"RECRUITING","sponsor":"Ruijun Ji","startDate":"2024-08-01","conditions":"Ischemic Stroke","enrollment":300},{"nctId":"NCT07016854","phase":"NA","title":"Early Endovascular Treatment in Isolated Internal Carotid Artery Occlusion","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-06","conditions":"Stroke, Acute Ischemic","enrollment":140},{"nctId":"NCT06115070","phase":"PHASE4","title":"Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Thrombosis, Acute Ischemic Stroke (AIS)","enrollment":390},{"nctId":"NCT06841965","phase":"PHASE3","title":"Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Stroke, Acute Ischemic Stroke","enrollment":280},{"nctId":"NCT06841978","phase":"PHASE3","title":"Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Stroke, Acute Ischemic Stroke","enrollment":306},{"nctId":"NCT02398656","phase":"PHASE3","title":"A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2015-04-01","conditions":"Stroke, Acute","enrollment":1274},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000},{"nctId":"NCT06498323","phase":"PHASE4","title":"Intravenous TNK vs TPA for AIS Treatment on MSU,a Prospective Multicenter RCT","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2022-08-03","conditions":"Intravenous, Thrombosis, Acute Ischemic Stroke","enrollment":160},{"nctId":"NCT05105633","phase":"PHASE2, PHASE3","title":"Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke","status":"RECRUITING","sponsor":"University of Melbourne","startDate":"2021-11-29","conditions":"Basilar Artery Occlusion","enrollment":688},{"nctId":"NCT04261478","phase":"NA","title":"Endovascular Acute Stroke Intervention - Tandem OCclusion Trial","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2020-08-31","conditions":"Stroke, Acute, Carotid Stenosis, Carotid Artery Diseases","enrollment":458},{"nctId":"NCT04420351","phase":"PHASE3","title":"Thrombolysis of Urokinase for Minor Stroke","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2020-10-04","conditions":"Minor Stroke","enrollment":1005},{"nctId":"NCT05902000","phase":"NA","title":"Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion","status":"UNKNOWN","sponsor":"Xueli Cai","startDate":"2023-06-14","conditions":"Thrombectomy, Tandem Occlusion, Stroke","enrollment":222},{"nctId":"NCT05634382","phase":"PHASE3","title":"Endovascular Thrombectomy With and Without Intravenous Thrombolysis in Extended Time Window","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-12-03","conditions":"Stroke, Acute Ischemic","enrollment":222},{"nctId":"NCT05493163","phase":"PHASE4","title":"Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism","status":"RECRUITING","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2022-10-19","conditions":"Pulmonary Embolism","enrollment":558},{"nctId":"NCT03494920","phase":"PHASE3","title":"DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval Versus Standard Bridging Thrombolysis With Endovascular Clot Retrieval","status":"COMPLETED","sponsor":"Neuroscience Trials Australia","startDate":"2018-04-27","conditions":"Ischemic Stroke","enrollment":295},{"nctId":"NCT05354128","phase":"NA","title":"Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak.","status":"UNKNOWN","sponsor":"Ya-Wei Xu","startDate":"2022-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":120},{"nctId":"NCT01694381","phase":"EARLY_PHASE1","title":"Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor","status":"TERMINATED","sponsor":"TSI, LLC","startDate":"2012-09","conditions":"Acute Ischemic Stroke","enrollment":8},{"nctId":"NCT03340493","phase":"PHASE2","title":"Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)","status":"COMPLETED","sponsor":"Neuroscience Trials Australia","startDate":"2017-12-06","conditions":"Ischemic Stroke","enrollment":300},{"nctId":"NCT03595085","phase":"NA","title":"Catheter Directed Interventions in Pulmonary Embolism","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-09-01","conditions":"Pulmonary Embolism","enrollment":60},{"nctId":"NCT01123161","phase":"PHASE2, PHASE3","title":"The Intravascular Cooling in the Treatment of Stroke 2/3 Trial","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2010-06","conditions":"Stroke, Acute","enrollment":120},{"nctId":"NCT00894803","phase":"PHASE2","title":"Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2009-07","conditions":"Ischemic Stroke, Stroke, Brain Infarction","enrollment":126},{"nctId":"NCT01455935","phase":"PHASE2","title":"Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention","status":"UNKNOWN","sponsor":"Jacobs Neurological Institute","startDate":"2011-11","conditions":"Stroke","enrollment":90},{"nctId":"NCT00799968","phase":"PHASE4","title":"12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2002-06","conditions":"Pulmonary Embolism, Thromboembolism","enrollment":129}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intravenous thrombolysis agents","genericName":"Intravenous thrombolysis agents","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravenous thrombolysis agents dissolve blood clots by converting plasminogen to plasmin, which breaks down fibrin and restores blood flow in occluded vessels. Used for Acute ischemic stroke, Acute myocardial infarction, Pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}